

Short Communications

ID	N.pgm	Title	Presenting Author
22/05/2025 10.05 - 11.05 HIV 2025: disparities and trajectories			
34	SC 1	Integrating HPV vaccination promotion into community-based sexual health services: an empowerment approach	Marco Stizioli, Brescia
42	SC 2	Fast track health path: screening, information and care of fragile people in Rome	Paola Sammarco, Roma
148	SC 3	When Health Services are Hard to Reach: Insights from a mobile HIV/STI programme for migrant sex workers	Chiara Soligo, Milano
278	SC 4	Poor retention in care among transgender women living with HIV(TWLWH): a call for targeted interventions	Pierluigi Francesco Salvo, Roma
336	SC 5	STIs Testing Among Young People: Strategies, Results, and Educational Implications	Caterina Pellegris, Chioduno BG
321	SC 6	Promoting Hepatitis and HIV screening in high prevalence populations: the 'Test in the City' Project	Ilaria Mercurio, Chioduno BG
22/05/2025 11.10 - 12.10 ART and comorbidities			
15	SC 7	Management of polypharmacy and potential drug-drug interactions in people with HIV and cancer: insights from a 4-year multidisciplinary clinic experience	Cristina Gervasoni, Milano
272	SC 8	Neurocognitive impairment over time in people with HIV (PWH) with and without cerebrospinal viral escape (CHVE)	Carmela Pinnetti, Roma
287	SC 9	Comparison between the Frascati criteria and Equivalent Scores for the neurocognitive assessment (NCA) of people living with HIV (PWH)	Giulia Del Duca, Rome
330	SC 10	Atherogenic Index of Plasma as a Predictor of Cardiovascular Events in People living with HIV: Evidence from the ICONA Cohort	Nicola Squillace, Monza
194	SC 11	Critical illness in people with HIV (PWH). Temporal trends, reasons for admission, and mortality of PWH admitted to ICU from 2010 to 2024. The experience of two Italian referral centres	Federica La Fata, Roma
106	SC 12	Correlation among lipid profile, subclinical atherosclerosis and hepatic steatosis in PLWH: the role of inflammation	Antonietta Boccia, Napoli
22/05/2025 12.15 - 13.15 Open issues in virology and pharmacology			
109	SC 13	Plasma SARS-CoV-2 RNA associates with disease severity during acute infection but not with persistent symptoms	Roberta Rovito, Milano
319	SC 14	The potential impact of pharmacogenetics on bulevirtide plasma exposure in the clinical setting	Jessica Cusato, Torino
276	SC 15	Clinical and laboratory parameters correlated to HDV undetectability after 48 weeks of bulevirtide	Andrea Di Lorenzo, Roma
146	SC 16	Analysis of HIV proviral integration sites in the host genome of PWH with a virus displaying amino acid polymorphism in the integrase C-terminal region	Isabella Abbate, Roma
234	SC 17	Performance of a Next-generation Sequencing Test for HIV Drug Resistance Analysis in Proviral HIV-DNA	Tiziano Giacomo Alice, Torino
226	SC 18	Long acting cabotegravir and rilpivirine plasma and intracellular pharmacokinetics in the clinical setting after 2-year follow-up	Micol Ferrara, Torino



Short Communications

ID	N.pgm	Title	Presenting Author
22/05/2025 15.10 - 16.10 Data that matter: epidemiological realities of HIV in the modern era			
17	SC 19	Incidence of new HIV diagnoses in Italy: a comparison with major Western European countries	Vincenza Regine, Roma
96	SC 20	Comparison of new HIV diagnosis incidence between Italians and foreigners present in Italy from 2012 to 2023: analysis of the increase post- COVID19 pandemic	Raffaello Iacono, Roma
174	SC 21	A survey on the continuum of care for HIV in sex-workers in Italy: the contribution of NGOs	Elisabetta Gennaro, Roma
300	SC 22	HBV and HCV Testing in Italy's Marginalized Groups: Advancing WHO's 2030 Elimination Goal	Teresita Caruso, Pisa
213	SC 23	Characteristics of people living with HIV who were lost to follow-up	Laura Comi, Bergamo
23	SC 24	All-Cause Mortality in People with Four-Class Drug-Resistant HIV: A Matched Cohort Analysis with Data from the PRESTIGIO Registry	Andrea Giacomelli, Milano
22/05/2025 16.15 - 17.25 Deep insights in two-drug antiretroviral regimen			
40	SC 25	Comparable dynamics of cell-associated HIV-RNA, total and intact proviral HIV-1 DNA in virologically suppressed people with HIV switching to 2DR or continuing 3DR over a 18-month follow-up	Niccolò Bartolini, Siena
160	SC 26	Effectiveness of first-line lamivudine-dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort	Alessandro Cozzi-Lepri, London UK
235	SC 27	Real-world experience with Doravirine in Italy: comparing three-drug and two-drug regimens	Adriana Cervo, Modena
311	SC 28	Adverse event development in people with HIV on long-acting Cabotegravir + Rilpivirine: timing and clinical insights	Gaia Cologgi, Genova
326	SC 29	Reasons for declining Long-Acting-Injectable therapy in eligible PLWH: insights from the WHY-Not study	Layla Pagnucco, Pavia
75	SC 30	Real-World Discontinuation and Virological Outcomes of Long-Acting Cabotegravir + Rilpivirine in virologically suppressed adults living with HIV: A Multicenter Observational Study in Tuscany (LAHIV)	Filippo Lagi, Firenze
169	SC 31	Durability, Adherence, and Discontinuation of Long-Acting Cabotegravir/Rilpivirine: A 96-Week Real-World Study	Davide Moschese, Milano
23/05/2025 15.05 - 16.05 From epidemiology to innovation: vaccine coverage and viral pathogenesis			
41	SC 32	Implementation of a monitoring system for immunization coverage in people living with HIV in the Lombardy region	Manuel Maffeo, Milano
151	SC 33	Implementing the National Vaccination Plan in People with HIV (PWH): a national survey among ICONA centers	Antonio Russo, Napoli
178	SC 34	Generation of a novel and safe viral-based neutralization assay for monitoring Flavivirus emerging and re-emerging zoonoses	Alessandra Gallinaro, Roma
131	SC 35	Incidence and Risk Factors of HPV-16 Clearance at the Anal Site in MSM with HIV	Elena Bruzzesi, Milano
93	SC 36	G-Quadruplexes are Molecular Switches in HIV-1 Latency Regulation	Emanuela Ruggiero, Padova
315	SC 37	Low-level viremia during antiretroviral treatment is not associated with impaired immunological recovery in the second-generation INSTI era	Tommaso Clemente, Milano



*No boundaries in
 Infection Research
 and Care*

Short Communications

ID	N.pgm	Title	Presenting Author
23/05/2025 15.05 - 16.05 Challenges in prevention			
257	SC 38	Predictors of STI reinfection in a monocentric cohort of high-risk men who have sex with men	Pierluigi Francesco Salvo, Roma
153	SC 39	Mpox vaccination and natural immunity: a comparative serological study	Donatella Maddalena, Milano
50	SC 40	Macrolide-resistant Mycoplasma genitalium: epidemiological insights from a clinical study in high-risk populations	Giancarlo Ciacchioli, Milano
119	SC 41	One-year experience in HIV non-occupational post-exposure prophylaxis (nPEP) management at Jenner 44 STI clinic - Luigi Sacco Hospital, Milan, Italy: focus on adherence	Laura Cordier, Milano
341	SC 42	Burden of Anal High Grade Dysplasia is High Among an Under-screened Population Such as Women Living With HIV	Eugenio Nelson Cavallari, Roma
339	SC 43	Is DoxyPEP Being Overused? Insights from a PrEP Clinic Cohort	Francesco Caruso, Milano